Levodopa-Induced Dyskinesia in Parkinson's Disease

Clinical Trial Title

A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson’s Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and its Individual Components (Protocol No. BK-JM-201)

National Clinical Trial Number:

NCT04377945

Contact Information

Jessica Tartakovsky

Clinical Trial Protocol Description:

The purpose of this study is to determine if the investigational study drug, JM-010, is safe and effective in the treatment of levodopa-induced dyskinesia (involuntary movements) in participants with Parkinson’s disease.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Be between 18 and 80 years of age
  • Be diagnosed with Parkinson’s disease (PD) and taking a stable dose of levodopa 3 to 6 times daily
  • Have muscle twitches and twisting movement (dyskinesia) that is moderately to completely disabling (more than one hour per day)

You will be excluded from the study if:

  • Have had surgery for treatment of Parkinson’s disease
  • Have a current diagnosis of Substance Abuse Disorder or psychiatric conditions.

This is a partial list of inclusion and exclusion criteria.

Study Details

Clinical Trial Investigator

Neepa J. Patel, MD

Contact Information

Jessica Tartakovsky

Clinical Trial Location

Rush University Medical Center

Location

Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more